Leerink Predicts $5,000 Price For Remdesivir, Higher Than ICER’s Range

By John Wilkerson / June 3, 2020 at 5:26 PM
Wall Street analyst Leerink believes Gilead will eventually sell courses of remdesivir for $5,000, more than the high end of the range that the drug price evaluating nonprofit Institute for Clinical and Economic Review suggested last month. Leerink estimates Gilead could sell $7.6 billion worth of the antiviral in 2022, with sales falling off thereafter. Remdesivir is the only drug to show modest improvements in COVID-19 patients. Gilead donated 1.5 million doses of it globally, and the United States received...


Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.